Hear from Our Experts

An insightful exploration into the HBV landscape, how ARCUS gene editing is unique among other genetic modalities in development, details regarding the upcoming PBGENE-HBV clinical trial, and more.

HBV Currently Lacks a Curative Treatment

Hepatitis B is a leading cause of morbidity in the US and death globally, with no current curative options

> 1,000,000
cHBV infections in the US

> 300 million
cHBV infections globally

An estimated

15% to 40% of patients

with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths.

Current HBV treatments require life-long chronic treatment that may result in viral suppression by reducing circulating HBV DNA, but these therapies do not eradicate HBV cccDNA and therefore rarely lead to functional cure. 

Functional Cure
=
Sustained Undetectable Circulating HBV Surface Antigen (HBsAg) and HBV DNA After a Finite Course of Treatment. 

PBGENE-HBV:

ARCUS Uniquely Targets HBV
by eliminating cccDNA and inactivating integrated HBV DNA

Current Therapeutic Strategies
are limited and do not target the root cause of disease – viral replication

HBV Mechanism of Infection


Reasons to Believe in Precision’s Approach for HBV

ARCUS is only approach for HBV targeting both elimination of and inactivation of integrated HBV DNA
Up to 99% viral engagement after a finite course of treatment in preclinical animal models
Precision has made platform improvements 8-fold increase in ARCUS protein expression, designed to boost efficacy
In vivo gene editing offers a novel approach for HBV patients and a path for a functional cure; target CTA and/or IND in 2024